International Clinical Trial: Efficacy and safety of ipilimumab in combination with bevacizumab as first-line treatment in advanced cutaneous and acral melanoma: a prospective, single-arm clinical study

Geneva, Oct. 15 -- International Clinical Trials Registry received information related to the study (ChiCTR2600134147) titled 'Efficacy and safety of ipilimumab in combination with bevacizumab as first-line treatment in advanced cutaneous and acral melanoma: a prospective, single-arm clinical study' on Oct. 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Anyang Tumour Hospital

Condition: Locally advanced adenocarcinoma of the gastroesophageal junction

Recruitment Status: Recruiting

Phase: N/A

Date of First Enrollment: 2026-01-08

Target Sample Size: Experimental group:34;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=298063

Published by HT Di...